Section Arrow
Quote
TSBX.NASDAQ
- Turnstone Biologics Corp
(Financial Status)
Quotes are at least 15-min delayed:2025/03/13 18:15 EDT
Last
 0.3711
+0.017 (+4.80%)
Day High 
0.387 
Prev. Close
0.3541 
1-M High
0.4301 
Volume 
9.60K 
Bid
0.352
Ask
0.387
Day Low
0.361 
Open
0.368 
1-M Low
0.341 
Market Cap 
8.19M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.37 
20-SMA 0.38 
50-SMA 0.44 
52-W High 3.8782 
52-W Low 0.341 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.28/--
Enterprise Value
9.38M
Balance Sheet
Book Value Per Share
1.89
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
19.31M
Operating Revenue Per Share
1.73
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ADTXAditxt Inc0.0334-0.0234-41.20%0PE
CRVOCervoMed5.79-0.38-6.16%4.66PE
HEPAHepion Pharmaceuticals0.0378-0.011-22.54%-- 
IPAImmunoPrecise Antibodies Ltd0.405+0.0417+11.48%-- 
ONCOOnconetix Inc0.1298-0.0412-24.09%-- 
Quotes are at least 15-min delayed：2025/03/13 18:15 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.